MyShare
USLSEAU KLSEHKSG
user
Profile login
Help Center Ask Forum Keyboard Shortcuts

home

AMRN.US | summary | financial summary | prediction chart | global stock news | news graph | volatility | components |pairs | earnings | dividends | sales | compare

Assets: cash current-assets inventory receivables investments invested ppe nta assets net-debt working-capital liabilities long-term-debt accounts-payable non-current-liabilities

Income sheet sales operations-income gross-profit | expenses marketing r-and-d income-before-tax tax income net-income interest-income ebit leases interest earnings

Key Financials AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
symbollastchange%chngnamemcapsectorwiki
AMRN Amarin Corporation PLC 0.189B Healthcare wiki y

symbolprev.closerangecharttargetpercentperiodmonthsduerating
 C  AMRN 10.43 0,-0.997,0.376,0.610,-0.997 11.18,11.89,11.63,11.15,11.30,11.91,11.27,10.45,8.64,8.80,9.16,8.59,8.85,9.44,10.39 7.73-10.92 -10.60% 267,111,267 5.2 Jan 6-Sep 30 47.79%

1 AMRN US

The following extracted figures are selected by the AI as the most essential for predicting future price movements. The impact shows the impact of the figure on the share price forecast. Sometimes the impact of an increasing beneficial figure may still be downwards when the increase was smaller than expected. The over figure shows if the actual result was higher or lower than the AI would forecast.

Income statement

. Predection Dec 31,24 Sep 30,24 Jun 30,24 Mar 31,24 Dec 31,23
totalRevenue 57.0 62M 42M 68M 56M 75M
grossProfit -0.0 -10M 16M 42M 31M 45M
operatingIncome -56.0 -53M -25M -1M -14M -5M
. netInterestIncome 2.0 3M 3M 3M 3M 3M
incomeBeforeTax -57.0 -50M -22M 3M -9M -2M
taxProvision -0.0 -1M 4M 1M 1M 3M
netIncome -56.0 -49M -25M 2M -10M -6M
otherOperatingExpenses 105.0 115M 67M 68M 70M 80M
netIncomeApplicableToCommonShares
reconciledDepreciation 1.0 1M 1M 1M 1M 1M

Balance sheet

. Predection Dec 31,24 Sep 30,24 Jun 30,24 Mar 31,24 Dec 31,23
. itotalAssets 664.0 685M 751M 800M 790M 832M
totalCurrentAssets 579.0 595M 650M 702M 688M 725M
. cashAndShortTermInvestments 294.0 294M 306M 307M 309M 321M
. cash 126.0 121M 157M 216M 214M 200M
otherAssets
netWorkingCapital 357.0 415M 449M 471M 464M 466M
netInvestedCapital 430.0 486M 531M 552M 546M 552M
netDebt -142.0 -113M -149M -208M -206M -191M

Cash Flow

. Predection Dec 31,24 Sep 30,24 Jun 30,24 Mar 31,24 Dec 31,23
. totalCashFromOperatingActivities -9.0 -13M -2M -3M -13M -1M
. . depreciationAndAmortization 1.0 1M 1M 1M 1M 1M
. . . changeToAccountReceivables -2.0 -9M 11M -8M 18M -11M
. . freeCashFlow -8.0 -13M -2M -3M -13M -1M
. incomeTaxExpense. . -0.0 -1M 4M 1M 1M 3M

``` ```